Source-grounded facts extracted from Biofrontera Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Biofrontera Inc. shareholders approved Ratification of appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. at the 2026-06-11 meeting.
“Stockholders ratified the appointment of CBIZ CPAs P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The tabulation of votes cast was as follows: For Against Abstain Broker Non-Votes 10,905,016 723,806 1,311 0”
Biofrontera Inc. shareholders approved Approval of amendment and restatement of the Company's 2021 Omnibus Incentive Plan, including to increase the total number of shares of common stock authorized thereunder from 3,750,000 to 8,750,000. at the 2026-06-11 meeting.
“Stockholders approved the amendment and restatement of the Company's 2021 Omnibus Incentive Plan, including to increase the total number of shares of common stock authorized thereunder from 3,750,000 to 8,750,000. The tabulation of votes cast was as follows: For Against Abstain Broker Non-Votes 7,893,236 241,359 175,881 3,319,657”
Biofrontera Inc. shareholders approved Stockholders elected Beth J. Hoffman, Ph.D. and Kevin D. Weber to serve as Class II directors of the Company until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. at the 2026-06-11 meeting.
“Stockholders elected Beth J. Hoffman, Ph.D. and Kevin D. Weber to serve as Class II directors of the Company until the 2029 Annual Meeting of Stockholders and until his or her successor has been duly elected and qualified, or until his or her earlier death, resignation, or removal. The tabulation of votes cast was as follows: Beth J. Hoffman, Ph.D. For Withheld Broker Non-Votes 8,089,416 221,060 3,319,657 Kevin D. Weber For Withheld Broker Non-Votes 8,203,433 107,043 3,319,657”
Biofrontera Inc. reported first quarter of 2026 results: revenue $10.1 million, net income $4.8 million, or $0.41 per share, EPS $0.41 per share.
“today reported financial results for the three months ended March 31, 2026 and provided a business update. First Quarter Financial Highlights ● Revenues for Q1 2026 were $10.1 million, a ~17% increase compared to $8.6 million for the same period in 2025. ● Gross margins were about 80%, an 18 percentage points increase compared to approximately 62% in Q1”
Biofrontera Inc. reported the fiscal year ended December 31, 2025 results: revenue $41.7 million, net income $10.5 million.
“GAAP to non-GAAP reconciliation of Adjusted EBITDA for the fourth quarters of 2025 and 2024. Full Year 2025 Financial Results Total revenues for full year 2025 increased 12% to $41.7 million compared with $37.3 million for the full year 2024. Gross profit margin for the full year 2025 was 73.7% compared to 50.1% for the prior year. Cost of goods sold related party”
Biofrontera Inc. reported the fourth quarter ended December 31, 2025 results: revenue $17.1 million, net income $5.6 million.
“financial results for the three and twelve months ended December 31, 2025 and provided a business update. Fourth Quarter Financial Highlights ● Revenues for 4Q25 were a record $17.1 million, a 36% increase compared to $12.6 million for the same period in 2024. ● Gross margins were 82.4%, a roughly 2,400 basis point year over year increase compared to 58.0% in”
Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 34 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un”
Biofrontera Inc. completed a disposition involving Pelthos Therapeutics Inc. for maximum of $10,000,000 (closed 2025-11-06).
“Capitalized terms used below that are not defined herein shall have the meanings ascribed to such terms in the APA. The purchase price for the Acquired Assets is a maximum of $10,000,000, payable as follows: 1) $3,000,000 in cash, paid on the Closing Date; 2) Subject to availability of certain commercial quantities of the Product and other terms and conditions of”
Biofrontera Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1), 5550(b)).
“May 21, 2025, Biofrontera Inc. (the “Company”) received a letter (the “Notice”) from The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended March 31, 2025 was $469,000, the Company is no longer in compliance with the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000. Additionally, as of the date of the Notice, the Company did not meet either of the alternative requirements of”
Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“May 8, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 33 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Under Na”
Biofrontera Inc. engaged CBIZ CPAs P.C. as its auditor.
“On April 17, 2025, Marcum resigned as the independent registered public accounting firm of Biofrontera Inc. (the “Company”) and, with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”
Marcum LLP resigned as auditor of Biofrontera Inc..
“On April 17, 2025, Marcum resigned as the independent registered public accounting firm of Biofrontera Inc. (the “Company”) and, with the approval of the Audit Committee of the Company’s Board of Directors, CBIZ CPAs was engaged as the Company’s independent registered public accounting firm for the year ending December 31, 2025.”
Biofrontera Inc. reported the three months ended March 31, 2024 results: revenue $7.9 million, net income $10.4 million, or $(2.88) per share, EPS $(2.88) per share.
“2024 and provided a business update. Highlights from the first quarter of 2024 and subsequent weeks included the following: ● Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breach ● Cash and”
Biofrontera Inc.: Increased authorized shares of common stock from 15,000,000 to 35,000,000 (effective 2024-04-25).
“On April 25, 2024, Biofrontera Inc. (the “Company”) filed a Certificate of Second Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to increase the number of the Company’s authorized shares of common stock, par value $0.001, from 15,000,000 to 35,000,000.”
Biofrontera Inc. reported the fourth quarter of 2023 results: revenue $10.6 million, net income $3.5 million, EPS $1.65 per share.
“Total revenues for the fourth quarter of 2023 were $10.6 million, an increase of $0.5 million, or ~4%, compared with $10.1 million for the fourth quarter of 2022.”
Biofrontera Inc. reported financial results for the three and twelve months ended December 31, 2023.
“On March 15, 2024, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2023.”
Biofrontera Inc.: Filed Certificate of Designation for Series B Preferred Stock, establishing rights, preferences, and limitations of three new series of preferred stock (effective 2024-02-20).
“on February 20, 2024, the Company filed the Certificate of Designation with the Delaware Secretary of State designating 6,586 shares of its authorized and unissued preferred stock as Series B-1 Preferred Stock, 6,586 shares as Series B-2 Preferred Stock and 8,000 shares as Series B-3 Convertible Preferred Stock”
Biofrontera Inc. entered into Securities Purchase Agreement with accredited investors (Preferred Investors) valued at $8,000,000 (effective 2024-02-19).
“On February 19, 2024, the Company entered into a securities purchase agreement (the “ Purchase Agreement ”) with certain accredited investors (the “ Preferred Investors ”), pursuant to which the Company agreed to issue and sell, in a private placement (the “ Offering ”), (i) 6,586 shares of Series B-1 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-1 Preferred Stock ”), and (iii) warrants (the “ Preferred Warrant ”) to purchase shares of Series B-3 Convertible Preferred Stock, par value $0.001 per share (the “ Series B-3 Preferred Stock ”) for an aggregate offering price of $8.0 million.”
Biofrontera Inc. entered into Second Amended and Restated License and Supply Agreement with Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH valued at Transfer price changed to 25% through 2025 then increasing up to 35% starting in 2032 (effective 2024-02-13).
“On February 19, 2024, Biofrontera Inc. (the “ Company ”) entered into the Second Amended and Restated License and Supply Agreement (the “ LSA ”), effective as of February 13, 2024 , by and among the Company, Biofrontera Pharma GmbH (“ Pharma ”), and Biofrontera Bioscience GmbH (“ Bioscience ”).”
Biofrontera Inc. amended LSA with Biofrontera Pharma GmbH, Biofrontera Bioscience GmbH, Biofrontera AG (effective 2024-01-26).
“On January 29, 2024, Biofrontera Inc. (the “ Company ”) entered into an amendment and restatement (the “ Amendment ”), effective January 26, 2024, of an Addendum (the “ Addendum ”), entered into on December 12, 2023, to its Amended and Restated License and Supply Agreement, dated as of June 16, 2021 (as previously amended, the “LSA”), by and among the Company, Biofrontera Pharma GmbH (“Pharma”), and Biofrontera Bioscience GmbH (“Bioscience”).”
Biofrontera Inc. reported preliminary financial results for three and twelve months ended December 31, 2023.
“On January 11, 2024 Biofrontera Inc. (the "Company") issued a press release announcing its preliminary unaudited revenues for the fourth quarter and full year ended December 31, 2023.”
Biofrontera Inc. terminated MidCap Loan Agreement with MidCap valued at prepayment fee of $150,000 (effective 2024-01-04).
“Effective as of January 4, 2024, the Company terminated the MidCap Loan Agreement. In connection with the termination, the Company paid a $150,000 prepayment fee to MidCap.”
Biofrontera Inc. entered into Share Transfer Agreement with Maruho Deutschland GmbH valued at Transfer of 5,451,016 shares of Biofrontera AG stock to Maruho; release of $7.3 million start-up cos (effective 2023-12-22).
“On December 29, 2023, Biofrontera, Inc. (the "Company"), entered into a Confidential Settlement Agreement and Mutual Release (the "Release"), dated as of December 27, 2023 and effective as of December 22, 2023, with Maruho Co. Ltd. ("Maruho"), and a Share Transfer Agreement (the "STA" and, together with the Release, the "Settlement Agreement"), dated as of December 27, 2023 and effective as of December 22, 2023, by and among the Company, Maruho, and Maruho Deutschland GmbH.”
Biofrontera Inc. entered into Confidential Settlement Agreement and Mutual Release with Maruho Co. Ltd. valued at Transfer of 5,451,016 shares of Biofrontera AG stock to Maruho; release of $7.3 million start-up cos (effective 2023-12-22).
“On December 29, 2023, Biofrontera, Inc. (the "Company"), entered into a Confidential Settlement Agreement and Mutual Release (the "Release"), dated as of December 27, 2023 and effective as of December 22, 2023, with Maruho Co. Ltd. ("Maruho"), and a Share Transfer Agreement (the "STA" and, together with the Release, the "Settlement Agreement"), dated as of December 27, 2023 and effective as of December 22, 2023, by and among the Company, Maruho, and Maruho Deutschland GmbH.”
Biofrontera Inc. incurred term loan of $2,000,000 with Lender B maturing July 5, 2024.
“and (b) a Business Loan and Security Agreement ("Agreement B" and together with the Agreement A, the "Loan Agreements") pursuant to which the lender ("Lender B") has made a term loan to the Company in the principal amount of $2,000,000 (the "Loan B" and together with the Loan A, the "Loans"), evidenced by a Secured Promissory Note, effective as of December 21, 2023 ("Note B"), made by the Company in favor of Lender B.”
Biofrontera Inc. incurred term loan of $2,000,000 with Lender A maturing July 5, 2024.
“On December 21, 2023, Biofrontera, Inc. (the "Company") entered into (a) a Business Loan and Security Agreement (the "Agreement A") pursuant to which the lender ("Lender A") has made a term loan to the Company in the principal amount of $2,000,000 ("Loan A"), evidenced by a Secured Promissory Note, effective as of December 21, 2023 ("Note A"), made by the Company in favor of Lender A”
Biofrontera Inc. terminated Revolving line of credit with MidCap Business Credit LLC with MidCap Business Credit LLC valued at Voluntary termination of revolving line of credit that provided for maximum borrowings of $6.5 milli.
“In connection with entering into the Agreement A and Agreement B, the Company is in the process of voluntarily terminating the revolving line of credit between the Company and MidCap Business Credit LLC that provided for maximum borrowings of $6.5 million, subject to a borrowing base and an availability block.”
Biofrontera Inc. entered into Business Loan and Security Agreements A and B with Lender A and Lender B valued at Two term loans of $2,000,000 each, total $4,000,000 (effective 2023-12-21).
“On December 21, 2023, Biofrontera, Inc. (the “Company”) entered into (a) a Business Loan and Security Agreement (the “Agreement A”) pursuant to which the lender (“Lender A”) has made a term loan to the Company in the principal amount of $2,000,000 (“Loan A”), evidenced by a Secured Promissory Note, effective as of December 21, 2023 (“Note A”), made by the Company in favor of Lender A; and (b) a Business Loan and Security Agreement (“Agreement B” and together with the Agreement A, the “Loan Agreements”) pursuant to which the lender (“Lender B”) has made a term loan to the Company in the principal amount of $2,000,000 (the “Loan B” and together with the Loan A, the “Loans”), evidenced by a Secured Promissory Note, effective as of December 21, 2023 (“Note B”), made by the Company in favor of Lender B.”
Biofrontera Inc. shareholders approved Ratification of Appointment of Independent Public Accounting Firm (Marcum LLP) at the 2023-12-20 meeting.
“Ratification of Appointment of Independent Public Accounting Firm For Against Abstain Broker Non-Votes 878,777 2,734 2,256 N/A”
Biofrontera Inc. shareholders approved Election of Beth J. Hoffman, Ph.D. and Kevin D. Weber as Class II Directors at the 2023-12-20 meeting.
“Beth J. Hoffman, Ph.D. For Withheld Broker Non-Votes 531,471 9,810 342,486”
Biofrontera Inc. entered into Addendum to Amended and Restated License and Supply Agreement with Biofronter Pharma GmbH, Biofrontera Bioscience GmbH, and Biofrontera AG valued at Schedule of payments for purchase of Licensed Products through end of 2024 (effective 2023-12-12).
“On December 12, 2023, Biofrontera Inc. (the “ Company ”) entered into an addendum (the “ Addendum ”) to its Amended and Restated License and Supply Agreement, dated as of June 16, 2021 (as amended on October 8, 2021, the “LSA”), by and among the Company, Biofrontera Pharma GmbH (“Pharma”), and Biofrontera Bioscience GmbH (“Bioscience”).”
Biofrontera Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“November 22, 2023, Biofrontera Inc. (the “Company”) received a notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, because the Company’s stockholders’ equity as reported in its Quarterly Report on Form 10-Q for the period ended September 30, 2023 was $1,038,000, the Company is no longer in compliance with the continued listing requirement under Nasdaq Listing Rule 5550(b)(1), which requires that a listed company’s stockholders’ equity be at least $2,500,000. Additionally, as of the date of the Notice, the Company did not”
Biofrontera Inc. reported three and nine months ended September 30, 2023 results: revenue $8.9 million, net income $(4.64) per share, EPS $(4.64) per share. Guidance reaffirmed.
“Total revenues for the third quarter of 2023 were $8.9 million”
Biofrontera Inc. amended Existing Warrants Amendment with an institutional investor valued at Amendment to revise exercise price to $3.55 and extend expiration date to November 2, 2028 (effective 2023-10-30).
“On October 30, 2023, in connection with the Purchase Agreement, the Company entered into an amendment to the Existing Warrants (the “ Existing Warrants Amendment ”) pursuant to which the Company agreed, effective November 2, 2023, to (i) revise the exercise price of the Existing Warrants to $3.55 and (ii) extend the date until which the Existing Warrants can be exercised until November 2, 2028.”
Biofrontera Inc. entered into Placement Agency Agreement with Roth Capital Partners, LLC valued at Gross proceeds of approximately $4.5 million from sale of 1,205,000 shares of common stock and warra (effective 2023-10-30).
“On October 30, 2023, Biofrontera Inc., a Delaware corporation (the “Company”), entered into a placement agency agreement (the “ Placement Agency Agreement ”) with Roth Capital Partners, LLC (the “ Placement Agent ”) and a securities purchase agreement (the “ Purchase Agreement ”) with an institutional investor for the purchase and sale, in a registered public offering by the Company (the “ Public Offering ”) of an aggregate of 1,205,000 shares of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), or pre-funded warrants to purchase Common Stock in lieu thereof, each of which is coupled with a warrant to purchase one and one-half shares of Common Stock.”
Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue $14.6 million, net income $17.3 million, EPS $(12.73) per share. Guidance reaffirmed.
“interest income and expense, income taxes, depreciation and amortization, and certain other non-recurring or non-cash items. Six Month Financial Results Total revenues were $14.6 million for the first half of 2023 compared with $14.2 million for the first half of 2022. The increase was primarily driven by a higher volume of Ameluz sales due to the sales team”
Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue $5.8 million, net income $9.8 million, EPS $(7.23) per share. Guidance reaffirmed.
“and six months ended June 30, 2023 and provided a business update. Highlights from the second quarter of 2023 and subsequent weeks included the following: ● Total revenues were $5.8 million, an increase of 31% from the comparable prior-year period ● Cash and cash equivalents were $4.5 million as of June 30, 2023, compared with $17.2 million as of December 31, 2022”
Biofrontera Inc. reported the six months ended June 30, 2023 results: revenue in the range of approximately $14.4 million to $14.6 million. Guidance reaffirmed.
“of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the range of approximately $14.4 million to $14.6 million, representing growth of approximately 1% to 3% compared with the first half of 2022. “We are proud of the hard work of our commercial teams, which resulted in”
Biofrontera Inc. reported the three months ended June 30, 2023 results: revenue in the range of approximately $5.7 million to $5.9 million. Guidance reaffirmed.
“announced preliminary unaudited revenues for the three months ended June 30, 2023. Revenues for the second quarter of 2023 are anticipated to be in the range of approximately $5.7 million to $5.9 million, an increase of approximately 26% to 31% compared with the second quarter of 2022. As a result, revenues for the first half of 2023 are anticipated to be in the”
Heikki Lanckriet was appointed as Director at Biofrontera Inc..
“On July 7, 2023, the board of directors (the “Board”) of Biofrontera Inc. (the “Company”) appointed Heikki Lanckriet to the Board.”
Grant Thornton LLP resigned as auditor of Biofrontera Inc..
“the Company’s prior registered independent public accountant Grant Thornton LLP resigned on May 30, 2023, as was disclosed in the Company’s Current Report on Form 8-K on June 2, 2023.”
Biofrontera Inc. engaged Marcum LLP as its auditor.
“On June 16, 2023 (the “Engagement Date”), Biofrontera Inc. (the “Company”) engaged Marcum LLP (“New Auditor”) as its independent registered public accounting firm for the Company’s fiscal year ended December 31, 2023.”
Grant Thornton LLP resigned as auditor of Biofrontera Inc..
“On May 30, 2023, Grant Thornton LLP ("GT") notified the Company of their resignation as the independent registered public accounting firm for the Company, effective immediately.”
Biofrontera Inc. shareholders approved Approval of proposal to adjourn the Special Meeting to a later date to permit further solicitation and vote of proxies in the event there are insufficient votes for the approval of the reverse stock split at the 2023-05-22 meeting.
“For Against Abstain Broker Non-Votes 14,804,169 734,168 35,233 0 As a result, the proposal was approved by a majority of the votes cast at the meeting.”
Biofrontera Inc. shareholders approved Approval of amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse split and decrease authorized shares at the 2023-05-22 meeting.
“For Against Abstain Broker Non-Votes 14,255,445 1,295,688 22,437 0 As a result, the Amendment was duly approved by the Company’s stockholders”
Biofrontera Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).
“May 23, 2023, Biofrontera Inc. (the “Company”) notified Nasdaq that, as a result of the resignation of Loretta Wedge as a member of the Board of Directors (the “Board”) of the Company and as chairperson of the Audit Committee, as described below, the Company was no longer in compliance with Nasdaq Listing Rule 5605(c)(2)(A), which requires that the audit committee of a listed company be composed of at least three independent directors and that at least one member of the audit committee is a financial expert. On May 25, 2023, John Borer, a member of the Board, was appointed to the audit committ”
Loretta Wedge resigned as Director at Biofrontera Inc..
“On May 22, 2023, the Company received a letter (the “Resignation Letter”) from Loretta Wedge tendering her resignation as a member of the Board.”
Erica Monaco resigned as Chief Executive Officer at Biofrontera Inc..
“Ms. Monaco would step down as Chief Executive Officer effective on May 26, 2023”
Hermann Luebbert was appointed as Chief Executive Officer at Biofrontera Inc..
“On May 25, 2023, the Board appointed Hermann Luebbert, the Company’s current Executive Chairman, to succeed Erica Monaco as the Company’s Chief Executive Officer as part of the transition of management responsibilities following the resignation of Ms. Monaco previously reported by the Company.”
Biofrontera Inc. reported first quarter ended March 31, 2023 results: revenue $8.7 million, EPS $(0.28) per share. Guidance reaffirmed.
“Total revenues for the first quarter of 2023 were $8.7 million compared with $9.8 million for the first quarter of 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.